Catalio Capital Management, LP 13F holdings, Q4 2024
Holdings as of December 31, 2024 · filings on SEC EDGAR · latest filing →
Catalio Capital Management, LP disclosed 33 US equity positions worth $457.1m in its Q4 2024 13F filing. The largest position was BDX at 7.4% of the reported book, followed by ASND and BMY.
What did Catalio Capital Management, LP own in Q4 2024? Top 33 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | BDX BECTON DICKINSON & CO | Healthcare | 7.4% | $33.7m | 148,615 | – | |
| 2 | ASND ASCENDIS PHARMA A/S | Healthcare | 6.5% | $29.7m | 215,587 | – | |
| 3 | BMY BRISTOL-MYERS SQUIBB CO | Healthcare | 6.2% | $28.2m | 499,151 | – | |
| 4 | SWTXUSD SPRINGWORKS THERAPEUTICS INC | 6.0% | $27.6m | 764,668 | – | ||
| 5 | 2655787D BLUEPRINT MEDICINES CORP | 5.4% | $24.8m | 284,654 | – | ||
| 6 | EW EDWARDS LIFESCIENCES CORP | Healthcare | 5.4% | $24.7m | 333,144 | – | |
| 7 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 5.4% | $24.7m | 898,458 | – | |
| 8 | LIVN LIVANOVA PLC | Healthcare | 5.2% | $23.7m | 512,447 | – | |
| 9 | SEPN SEPTERNA INC | 5.1% | $23.5m | 1,024,245 | – | ||
| 10 | CYTK CYTOKINETICS INC | Healthcare | 4.7% | $21.5m | 457,587 | – | |
| 11 | NVST ENVISTA HOLDINGS CORPORATION | Healthcare | 4.3% | $19.7m | 1,019,529 | – | |
| 12 | VCYT VERACYTE INC | Healthcare | 4.2% | $19.4m | 490,547 | – | |
| 13 | ISRG INTUITIVE SURGICAL INC | Healthcare | 4.2% | $19.3m | 36,910 | – | |
| 14 | EXK EXACT SCIENCES CORP | Basic Materials | 3.8% | $17.4m | 309,103 | – | |
| 15 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 3.6% | $16.6m | 763,471 | – | |
| 16 | QURE UNIQURE NV | 3.5% | $15.9m | 901,973 | – | ||
| 17 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 3.4% | $15.4m | 569,395 | – | |
| 18 | MASI* MASIMO CORP | 3.2% | $14.4m | 87,377 | – | ||
| 19 | IRON DISC MEDICINE INC | Healthcare | 2.5% | $11.4m | 179,815 | – | |
| 20 | ADMA ADMA BIOLOGICS INC | Healthcare | 1.9% | $8.8m | 512,724 | – | |
| 21 | NARIUSD INARI MED INC | 1.5% | $6.8m | 132,545 | – | ||
| 22 | BSX BOSTON SCIENTIFIC CORP | Healthcare | 1.4% | $6.5m | 72,925 | – | |
| 23 | KROS KEROS THERAPEUTICS INC | Healthcare | 1.4% | $6.4m | 407,292 | – | |
| 24 | TARA PROTARA THERAPEUTICS INC | 1.3% | $5.7m | 1,088,691 | – | ||
| 25 | MERSANA THERAPEUTICS INC | 0.5% | $2.4m | 1,705,036 | – | ||
| 26 | KYTX KYVERNA THERAPEUTICS INC | 0.5% | $2.2m | 586,909 | – | ||
| 27 | MGX METAGENOMI INC | 0.4% | $1.9m | 528,993 | – | ||
| 28 | KPTI KARYOPHARM THERAPEUTICS INC | Healthcare | 0.3% | $1.6m | 2,334,375 | – | |
| 29 | ZBIO ZENAS BIOPHARMA INC | 0.3% | $1.5m | 187,184 | – | ||
| 30 | HYPR HYPERFINE INC | 0.1% | $668.8k | 760,035 | – | ||
| 31 | GUTS FRACTYL HEALTH INC | 0.1% | $441.3k | 214,236 | – | ||
| 32 | ATAI LIFE SCIENCES NV | 0.1% | $261.8k | 196,858 | – | ||
| 33 | SNSEEUR SENSEI BIOTHERAPEUTICS INC | 0.0% | $144.3k | 294,374 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.